Table 1: Input parameters for model-based evaluation of Continuation and Discontinuation of antiplatelet medication in TKA patients with history of CAS surgery (in %).

Strategy Time interval between CAS and TKA
0-30 d 1- 6 mo 6 mo- 1 yr Range (%) Reference:
Discontinue APT Hematoma/
bleeding
31.0 9.3 2.4 0.2- 31.0 [17-19, 41]
Cardiac Event 23.2 9.5 7.0 6.0-37.5 [17, 20, 27-29, 42]
Death related to Cardiac Event 44.9 24.9 19.8 0.2-85.7 [6, 17, 22, 28, 34, 35, 42-44]
Continue of APT Hematoma/ bleeding 26.1 21.0 9.5 9.5- 43.8 [20-25]
Cardiac Event 7.4 3.2 3.0 0.6- 25.2 [5, 6, 21, 23, 25, 26]
Death related to Cardiac Event 12.3 8.3 3.2 0.2- 27.0 [4-6, 18, 22, 28, 35]
Common Variables
Infection after hematoma 11.9 11.9 [12, 13]
Death related to Infection 4.7 N/A [16]
Death unrelated to Infection and Cardiac Complications 0.2 N/A [45]